Home / Innere Medizin / Hämatologie und internistische Onkologie / ASCO 2018 – Daily Quizzes 13. June 2018 ASCO 2018 – Daily Quizzes Daily Quiz 1 Which statement on biomarkers of PD-(L)-1 expression is correct? (Select the correct answer) A The testing is carried out by means of a method that has since been standardized worldwide. B Low PD-(L)-1 expression correlates with poor response to checkpoint inhibitors. C As a biomarker for a response to checkpoint inhibitors PD-(L)-1 expression is only partially suitable. D Lack of PD-(L)-1 expression completely excludes the efficacy of checkpoint inhibitors. Submit Daily Quiz 2 Which statement about pseudoprogression under immunotherapy is correct? (Select the correct answer) A Patients with pseudoprogression should be advised not to continue immunotherapy. B A pseudoprogression on immunotherapy is a common event. C In a pseudoprogression, patients usually report a worsening of their symptoms. D The phenomenon is based on an infiltration of the tumor with lymphocytes. Submit Daily Quiz 3 Immune-related endocrine adverse events can last even after end of treatment. When can the first onset of hypophysitis under CTLA-4-inhibitor therapy typically be expected? (Select the correct answer) A Week 2–3 after start of therapy B Week 5–6 after start of therapy C Week 6–7 after start of therapy D Week 11–12 after start of therapy Submit Daily Quiz 4 Which of these biomarker statements are correct? (Select 3 answers) A Under PD-1-inhibitor therapy in non-melanoma tumors a correlation was shown between immune-related adverse events and longer time to next therapy or death. B Tumor mutational load is not a useful biomarker in the decision whether PD-1-Inhibition is the appropriate therapy. C Absolute neutrophil counts as well as neutrophil-to-lymphocyte ratio could be a reasonable part in a model identifying responders to checkpoint inhibitor therapy. D For the selection or exclusion of patients for treatment with checkpoint-inhibitor therapy no definitive biomarker does exist at the moment. Submit Daily Quiz 5 Which of these bacteria species as part of the gut microbioma were associated with response to immune checkpoint inhibition? (Select 3 answers) A Bacteroidales fragilis B Bifidobacterium C Faecalibacterium D Fusobacterium Submit Daily Quiz 6 Which endocrinopathies are most commonly observed related to immune checkpoint inhibitor therapy? (Select 3 answers) A Adrenal insufficiency B Hypothyroidism C Hyperthyroidism D Hypophysitis Submit Daily Quiz 7 What treatment is the standard of care in advanced BRAFV600-mutant melanoma? (Select the correct answer) A Pembrolizumab monotherapy B BRAF inhibitor therapy C Combined BRAF/MEK inhibitor therapy D Chemotherapy Submit Daily Quiz 8 Which of these statements are correct? (Select 3 answers) A Additive atezolizumab to chemotherapy delays progression in advanced squamous cell carcinoma of the lung. B Blood tests shows promising results as a detection tool for early-stage lung cancer. C The BFORE-study shows that patients with CML react better to Imatinib than to Bosutinib. D New Data suggest Pembrolizumab plus carboplatin and paclitaxel should become a new standard-of-care for first-line treatment of sq NSCLC. Submit Hint: You can find the answers in our videos and news articles Daily Quiz 9 Which of these statements on the Circulating Cell-Free Genome Atlas (CCGA) study are correct? (Select 3 answers) A The study provides preliminary evidence that a blood test may be able to detect early-stage lung cancer. B This is one of the first studies to explore blood tests analyzing free-floating or cell-free DNA as a tool for early detection of cancer. C Analysis of cell-free DNA from blood is already used to help choose targeted therapies, but these liquid biopsies are used only for people with advanced lung cancer. D The CCGA study has enrolled 6000 participants across 141 sites in the United States and Canada. Submit Daily Quiz 10 Which of these statements on urothelial carcinoma studies are correct? (Select 3 answers) A Atezolizumab is a PD-L1 inhibitor which is licenced in metastatic urothelial cancer. B Atezolizumab given after cystectomy in operable muscle invasive transitional cell carcinoma bladder cancer is safe and associated with a meaningful pathological CR rate. C Rogaratinib had a favorable safety profile and showed promising anti-tumor activity in urothelial cancer patients. D Enfortumab vedotin has encouraging ORR and PFS in heavily pretreated patients with metastatic urothelial cancer. Submit Hint: The answers can be found in Univ.-Prof. Dr. Shahrokh F. Shariat’s Breakfast Brief.